Australia thrashes out patient access deals for Soliris/Kalydeco
This article was originally published in Scrip
The Australian authorities are to start funding the use of Alexion's Soliris (eculizumab) for atypical hemolytic uremic syndrome (aHUS) and Vertex' Kalydeco (ivacaftor) for cystic fibrosis under the Pharmaceutical Benefits Scheme (PBS) from 1 December.
You may also be interested in...
What is next for the treatment of cystic fibrosis, a rare disease market that has boomed in recent years on the back of new drug approvals with hefty price tags? Pipelines are full, but securing reimbursement is a challenge.
New supply arrangements with the two firms are expected to offer greater protection to people in Europe as the autumn/winter season approaches. The EU’s health crisis preparedness body HERA has also identified its “top three health threats.”
A coordinated effort will be needed if Africa is to increase its manufacturing capacity and ensure a market for domestically produced vaccines.